首页> 美国卫生研究院文献>The Journal of Clinical Investigation >The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice
【2h】

The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice

机译:III型组蛋白脱乙酰基酶Sirt1对维持小鼠T细胞耐受性至关重要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although many self-reactive T cells are eliminated by negative selection in the thymus, some of these cells escape into the periphery, where they must be controlled by additional mechanisms. However, the molecular mechanisms underlying peripheral T cell tolerance and its maintenance remain largely undefined. In this study, we report that sirtuin 1 (Sirt1), a type III histone deacetylase, negatively regulates T cell activation and plays a major role in clonal T cell anergy in mice. In vivo, we found that loss of Sirt1 function resulted in abnormally increased T cell activation and a breakdown of CD4+ T cell tolerance. Conversely, upregulation of Sirt1 expression led to T cell anergy, in which the activity of the transcription factor AP-1 was substantially diminished. Furthermore, Sirt1 interacted with and deacetylated c-Jun, yielding an inactive AP-1 factor. In addition, Sirt1-deficient mice were unable to maintain T cell tolerance and developed severe experimental allergic encephalomyelitis as well as spontaneous autoimmunity. These findings provide insight into the molecular mechanisms of T cell activation and anergy, and we suggest that activators of Sirt1 may be useful as therapeutic agents for the treatment and/or prevention of autoimmune diseases.
机译:尽管胸腺中的阴性选择消除了许多自反应性T细胞,但其中一些细胞逃逸到外围,必须通过其他机制控制它们。但是,外周T细胞耐受性及其维持的分子机制仍未明确。在这项研究中,我们报告sirtuin 1(Sirt1),III型组蛋白脱乙酰基酶,负调控T细胞活化,并在小鼠克隆性T细胞无反应中起主要作用。在体内,我们发现Sirt1功能的丧失导致T细胞活化异常增加和CD4 + T细胞耐受性下降。相反,Sirt1表达的上调导致T细胞无反应,其中转录因子AP-1的活性大大降低。此外,Sirt1与c-Jun相互作用并使其脱乙酰,从而产生失活的AP-1因子。此外,Sirt1缺陷型小鼠无法维持T细胞耐受性,并发展出严重的实验性过敏性脑脊髓炎以及自发性自身免疫。这些发现提供了对T细胞活化和无能的分子机制的洞察力,我们建议Sirt1的活化剂可能用作治疗和/或预防自身免疫性疾病的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号